BioCryst to Present at Upcoming Investor Conferences
Tuesday, April 28, 2026 1 min read
Key Takeaway: BioCryst Pharmaceuticals has announced its participation in two upcoming investor conferences. The first will be at the Bank of America Health Care Conference on May 12, 2026, followed by the Jefferies Global Healthcare Conference on June 3, 2026. The company aims to present its advancements in treatments for hereditary angioedema and other rare diseases.
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
BioCryst is actively engaging with investors through multiple conferences.
The company is focused on rare diseases, showcasing its commitment to improving lives.
BioCryst has successfully commercialized ORLADEYO, indicating strong product development.
Full Press Release Details
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) --BioCryst Pharmaceuticals, Inc.(Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Bank of America Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 4:40 p.m. ET.
Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 3:45 p.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website atwww.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO®(berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visitwww.biocryst.comor follow us onLinkedIn.
When will BioCryst present at the investor conferences?
BioCryst will present at the Bank of America Health Care Conference on May 12, 2026, and at the Jefferies Global Healthcare Conference on June 3, 2026.
What is the focus of BioCryst Pharmaceuticals?
BioCryst focuses on developing treatments for hereditary angioedema and other rare diseases.
Where can I access the conference presentations?
Live audio webcasts and replays of the presentations will be available on BioCryst's website.
What product has BioCryst commercialized?
BioCryst has commercialized ORLADEYO, the first oral plasma kallikrein inhibitor.